CN117223848A - Powdered nutritional composition suitable for premature infants and preparation method thereof - Google Patents
Powdered nutritional composition suitable for premature infants and preparation method thereof Download PDFInfo
- Publication number
- CN117223848A CN117223848A CN202311238234.5A CN202311238234A CN117223848A CN 117223848 A CN117223848 A CN 117223848A CN 202311238234 A CN202311238234 A CN 202311238234A CN 117223848 A CN117223848 A CN 117223848A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- protein
- nutritional composition
- whey
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 98
- 230000002028 premature Effects 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 94
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 94
- 235000021119 whey protein Nutrition 0.000 claims abstract description 65
- 235000018102 proteins Nutrition 0.000 claims abstract description 53
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 238000001471 micro-filtration Methods 0.000 claims abstract description 37
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 30
- 239000011707 mineral Substances 0.000 claims abstract description 30
- 230000001954 sterilising effect Effects 0.000 claims abstract description 29
- 229940088594 vitamin Drugs 0.000 claims abstract description 29
- 229930003231 vitamin Natural products 0.000 claims abstract description 29
- 235000013343 vitamin Nutrition 0.000 claims abstract description 29
- 239000011782 vitamin Substances 0.000 claims abstract description 29
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 24
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 162
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 53
- 239000007788 liquid Substances 0.000 claims description 52
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 51
- 239000003921 oil Substances 0.000 claims description 48
- 235000019198 oils Nutrition 0.000 claims description 48
- 239000002994 raw material Substances 0.000 claims description 46
- 239000003925 fat Substances 0.000 claims description 43
- 235000019197 fats Nutrition 0.000 claims description 43
- 239000005913 Maltodextrin Substances 0.000 claims description 34
- 229920002774 Maltodextrin Polymers 0.000 claims description 34
- 229940035034 maltodextrin Drugs 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 32
- 239000005862 Whey Substances 0.000 claims description 29
- 235000010755 mineral Nutrition 0.000 claims description 29
- 235000020183 skimmed milk Nutrition 0.000 claims description 28
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 27
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 27
- 239000008158 vegetable oil Substances 0.000 claims description 27
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 26
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 25
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 25
- 235000021342 arachidonic acid Nutrition 0.000 claims description 25
- 229940114079 arachidonic acid Drugs 0.000 claims description 25
- 239000008101 lactose Substances 0.000 claims description 25
- 229960001375 lactose Drugs 0.000 claims description 25
- 238000001694 spray drying Methods 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 14
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- 239000008157 edible vegetable oil Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 239000007858 starting material Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims description 8
- 239000008601 oleoresin Substances 0.000 claims description 8
- 229940029985 mineral supplement Drugs 0.000 claims description 7
- 235000020786 mineral supplement Nutrition 0.000 claims description 7
- 235000019195 vitamin supplement Nutrition 0.000 claims description 7
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 6
- 239000012527 feed solution Substances 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 3
- 208000018773 low birth weight Diseases 0.000 abstract description 21
- 238000010438 heat treatment Methods 0.000 abstract description 15
- 239000004519 grease Substances 0.000 abstract description 7
- 230000000813 microbial effect Effects 0.000 abstract description 7
- 238000009928 pasteurization Methods 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 3
- 235000008452 baby food Nutrition 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 29
- 235000013350 formula milk Nutrition 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 22
- 235000019624 protein content Nutrition 0.000 description 20
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 19
- 235000019743 Choline chloride Nutrition 0.000 description 19
- 229960003178 choline chloride Drugs 0.000 description 19
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- 238000007580 dry-mixing Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000001035 drying Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 231100000533 low birth weight Toxicity 0.000 description 16
- -1 fatty acid ester Chemical class 0.000 description 15
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000012467 final product Substances 0.000 description 8
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 229960003067 cystine Drugs 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 238000005189 flocculation Methods 0.000 description 6
- 230000016615 flocculation Effects 0.000 description 6
- 235000020256 human milk Nutrition 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000006180 nutrition needs Nutrition 0.000 description 4
- 235000020601 preterm formula Nutrition 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 239000011265 semifinished product Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 235000020238 sunflower seed Nutrition 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241001135265 Cronobacter sakazakii Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 239000011665 D-biotin Substances 0.000 description 2
- 235000000638 D-biotin Nutrition 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 2
- 239000011706 ferric diphosphate Substances 0.000 description 2
- 235000007144 ferric diphosphate Nutrition 0.000 description 2
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 2
- 229940036404 ferric pyrophosphate Drugs 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 2
- 239000001230 potassium iodate Substances 0.000 description 2
- 235000006666 potassium iodate Nutrition 0.000 description 2
- 229940093930 potassium iodate Drugs 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 229940080237 sodium caseinate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 241000212959 Cryptotaenia Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000233671 Schizochytrium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- SLIUELDPAPMQIB-IDIVVRGQSA-N [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 Chemical compound [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 SLIUELDPAPMQIB-IDIVVRGQSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
Abstract
The invention belongs to the technical field of premature infant food research, and particularly relates to a powdery nutritional composition with high protein and high whey protein ratio and a preparation method thereof. The nutritional composition suitable for premature infants contains carbohydrate, protein, fat, mineral substances and vitamins; based on the total mass of the nutritional composition: the protein content is more than 3.5g/100kcal, and the whey protein accounts for 60-75% of the total protein by mass; and, the nutritional composition is a powdered solid. It can meet clinical nutritional requirements of premature infants/ultra-low birth weight infants. Meanwhile, the preparation method of the powdery nutritional composition provided by the invention adopts a microfiltration technology combined with an on-line adding mode of grease, overcomes the problem that the high-protein and high-whey-protein-ratio formula is denatured and flocculated by heat treatment, and timely increases pasteurization according to the microbial level of the material to perform secondary sterilization, thereby further reducing the microbial risk.
Description
Technical Field
The invention belongs to the technical field of premature infant food research, and particularly relates to a powdery nutritional composition suitable for premature infants and a preparation method thereof, and more particularly relates to a powdery nutritional composition with high protein and high whey protein ratio suitable for premature infants and a preparation method thereof.
Background
Premature/low birth weight infants are newborns with birth weights below 2500g indicating that the green gestational age is < 37 weeks. Premature infants can be further subdivided into late premature infants (34-36 weeks of gestational age), mid-term premature infants (32-33 weeks of gestational age), extremely premature infants (28-31 weeks of gestational age) and ultra-premature infants (28 weeks of gestational age); premature infants can be further subdivided into low birth weight infants (body weight 1.5-2.5 kg), very low birth weight infants (body weight 1-1.5 kg) and very low birth weight infants (< 1 kg) according to their birth weight. The premature infant is at double nutrition risk of high nutrient requirement but difficult nutrient absorption due to the fact that the premature infant misses the critical growth period of fetal development, namely the late pregnancy period, various nutrient reserves are less in the body after birth, and meanwhile, the brain, liver, kidney and gastrointestinal tract are immature in development and weak in digestion and absorption capacity. Premature infants with smaller gestational age are more affected by their immaturity, and nutritional deficiencies may be more pronounced in the initial adaptation phase after birth. The existing premature infant formula is designed based on the nutrition requirements of healthy extremely premature infants/extremely low birth weight infants or medium and late premature infants/low birth weight infants, and along with the continuous improvement of the survival rate of < 1kg of extremely low birth weight infants and ultra-premature infants with the gestational age of less than 28 weeks, the clinical nutrition requirements of the partial premature infants, in particular the nutrition requirements of proteins, become the focus of attention.
In addition to the amount of protein, the amount of protein is also a consideration in clinical feeding of premature infants. While the protein quality requirements for premature infants have not formed a uniform consensus, the protein quality in breast milk is an agreed upon gold standard. The ratio of whey protein to casein in breast milk is in dynamic change throughout lactation, ranging from 90:10 in the early stages of lactation (colostrum), 65:35 in transitional milk to 60:40 in mature milk and 50:50 in the late stages of lactation. Thus, a fortified formulation meeting the nutritional requirements of premature infants with birth weights < 1kg would have protein levels up to 3.6g/100kcal, and at least half would be derived from whey protein. Currently, there has been a study on high protein formula milk powder for premature infants, for example, reference 1 discloses a protein fortifier for altering the protein content in the nutrition of premature infants, thereby adapting the formula or human milk to the nutritional needs of very low birth weight children and very low birth weight children.
In addition, the existing milk powder production process comprises three processes of wet process, dry process and dry-wet process, and most of the existing milk powder production processes adopt the dry-wet process, and comprise the working procedures of mixing, homogenizing, sterilizing, concentrating, spray drying, dry mixing and the like. However, whey protein has thermal instability, and is easy to flocculate or precipitate when heated, so that the protein content in the formula is high, and when the whey protein occupies a relatively high proportion, the heat treatment processes such as sterilization and the like cannot be realized. Although the dry production can avoid the above problems, the microbial index of the product is not well controlled, and the risk of containing cronobacter sakazakii is high. Enterobacter sakazakii is a "conditional pathogen", which has been identified by the world health organization and many countries as an important conditional pathogen causing death of infants, and can cause illness in any age group of people, especially threat to premature/low birth weight infants or immunocompromised infants, severe one can cause sepsis, meningitis or necrotizing enterocolitis.
Microfiltration (MF) is a non-thermal processing technique that achieves separation based on component size differences and can be used for selective removal of bacteria and somatic cells from skim milk while maintaining the nutritional and bioactive components of the milk. Studies have shown that the microfiltration treatment of skim milk with a 1.4 μm pore size ceramic membrane at 50℃reduces the total colony count by 3.8lg CFU/mL, which is higher than the reduction of 1.7lg CFU/mL by high temperature short time sterilization (HTST) treatment. The pasteurized milk is produced by combining pasteurization and microfiltration, but the prior art needs to separate fat before microfiltration, filter and sterilize the skimmed milk, and the separated cream is independently subjected to heat treatment and sterilization and then is mixed with the sterilized skimmed milk, so that the application of the microfiltration technology in milk powder production is restricted by the characteristics.
In view of the above, it is important to develop a powdered nutritional composition suitable for premature infants with high protein and high whey protein ratio and to provide a preparation method thereof to ensure compliance of microbial indicators.
Citation literature:
citation 1: CN105941632a.
Disclosure of Invention
Problems to be solved by the invention
In order to realize the development of high-protein premature infant formulas, the prior art has conducted a number of studies, but by 2023, month 6, the national institute of market supervision has approved 13 special medical use premature/low birth weight infant formulas, all of which have protein contents of no more than 3.2g/100kcal, mostly designed at 2.6-3.0g/100kcal.
It can be seen that the prior art studies on premature infant formulas are still not said to be adequate, which is still not said to be fully adequate in terms of weight gain of ultra-premature infants/ultra-low birth weight infants to normal fetal levels of the same gestational age.
Further, the dry-wet method production process key points of the infant formula powder which are common at present comprise: (1) mixing: raw materials such as whey powder, lactose and the like, vitamins and minerals are fully dissolved in the batching equipment by using raw material milk, and then oil batching is uniformly mixed in the batching equipment. (2) Homogenizing: preheating the materials to 50-55deg.C for homogenizing under 18-20MPa. (3) Sterilizing: the materials are sterilized by heat treatment at 75-85 ℃ for 16-30 s. (4) Concentrating: concentrating the material to a concentrated milk density of 1000-1200kg/m 3 . (5) Spray drying: spray drying the material liquid at 165-190 deg.c and 68 deg.c85 ℃. (6) Dry blending: the unstable or heat sensitive raw materials are dry blended. When the preparation method is used for producing the formula of high protein and high whey protein, the whey protein in the feed liquid is subjected to heat treatment to cause flocculation and denaturation, so that a product meeting the standard requirement cannot be produced; and decreasing the heat treatment strength may present a microbiological risk.
However, in industrial practice, the present invention has found that, although it is desirable to further increase the protein content based on the existing products ("the protein content is not more than 3.2g/100kcal, most of which are designed to be 2.6-3.0g/100 kcal"), more macromolecular substances bring difficulty to the preparation process, such as problems of uniform mixing of materials and increased gel, which may be caused by thermal history (homogenization, sterilization, drying, etc.), resulting in that the existing processes and apparatuses cannot work normally and stably.
In this regard, the present invention provides a high protein, high whey protein ratio powdered nutritional composition suitable for premature infants suitable for wet blending processes and a method of preparing the same that allows for higher protein levels without affecting stable production. Specifically, the raw materials with higher microorganism risk are sterilized by a microfiltration technology, grease is added online in the homogenizing process, then pasteurized or directly concentrated, spray dried, and finally dry mixed with other micronutrients, thereby preparing the reinforced formula powder with protein content meeting the nutrition requirements of the ultra-premature infants/ultra-low birth weight infants.
Solution for solving the problem
In order to solve the technical problems, the invention provides the following technical scheme:
[1] a nutritional composition suitable for use in premature infants, wherein the nutritional composition comprises: carbohydrates, proteins, fats, minerals and vitamins;
and in the nutritional composition, based on the total mass of the nutritional composition: the protein content is more than 3.5g/100kcal, and the whey protein accounts for 60-75% of the total protein by mass;
and, the nutritional composition is a powdered solid.
[2] The nutritional composition according to [1], wherein the raw material of the nutritional composition comprises one or more of maltodextrin, skim milk powder, whey protein powder, desalted whey powder, edible oil, lactose, mineral supplements and vitamin supplements.
[3] The nutritional composition according to [2], wherein the edible oil or fat comprises one or more of vegetable oil, medium chain triglyceride, arachidonic acid oil and docosahexaenoic acid oil.
[4] The nutritional composition according to any one of [1] to [3], wherein the tap density of the nutritional composition is in the range of 180-220mL/100g.
[5] The method for producing a nutritional composition according to any one of [1] to [4], wherein the method comprises the steps of:
A step of mixing a raw material component I comprising carbohydrate and protein with water to obtain a premix liquid;
a step of micro-filtration sterilization of the premix liquid;
mixing the premixed material liquid after micro-filtration sterilization with a raw material component II comprising fat, homogenizing, concentrating, and spray drying to obtain semi-finished powder;
and a step of dry-blending the semi-finished powder with a raw material component III comprising minerals, vitamins and fat.
[6] The production method according to [5], wherein in the production method, between the steps of homogenizing and concentrating, a step of pasteurizing the homogenized feed liquid is further included.
[7] The process according to [5] or [6], wherein the temperature of the microfiltration is 40-50℃and the pore diameter of the microfiltration membrane is 0.8-1.6. Mu.m.
[8] The production method according to any one of [5] to [7], wherein the raw material component I comprises one or more of maltodextrin, skim milk powder, whey protein powder, desalted whey powder and lactose.
[9] The production method according to any one of [5] to [8], wherein the raw material component II comprises an edible oil or fat comprising a vegetable oil and a medium chain triglyceride.
[10] The production method according to any one of [5] to [9], wherein the raw material component III comprises a mineral supplement, a vitamin supplement, an arachidonic acid oleoresin powder and a docosahexaenoic acid oleoresin powder.
ADVANTAGEOUS EFFECTS OF INVENTION
By implementing the technical scheme, the invention has the following technical effects:
the invention firstly provides a powdery nutritional composition suitable for premature infants, the protein content of the composition is more than 3.5g/100kcal, even can reach 3.6g/100kcal, and whey protein accounts for 60-75 mass percent of the total protein, preferably can reach 60-70 mass percent, so that the composition can meet the clinical nutritional requirements of the premature infants/ultra-low birth weight infants.
Meanwhile, the invention also provides a preparation method of the powdery nutritional composition suitable for premature infants, which adopts a microfiltration technology and an on-line adding mode of grease to overcome the problem that the high-protein and high-whey-protein-ratio formula is denatured and flocculated by heat treatment, so that the powdery nutritional composition can be prepared in a large scale by a spray drying mode, and pasteurization is performed for secondary sterilization according to the microorganism level of materials at a proper time, thereby further reducing the microorganism risk.
Drawings
Fig. 1: the preparation process flow chart of the powdery nutritional composition provided by the application.
Fig. 2: the existing common milk powder preparation process flow chart.
Fig. 3: example 4 protein status (no denaturation, flocculation) in the concentrated feed solution during the preparation.
Fig. 4: comparative example 1 protein state (denaturation, flocculation) in the concentrated feed solution during the preparation.
Detailed Description
The following describes embodiments of the present application, but the present application is not limited thereto. The present application is not limited to the configurations described below, and various modifications are possible within the scope of the application as claimed, and embodiments and examples obtained by appropriately combining the technical means disclosed in the different embodiments and examples are also included in the technical scope of the present application.
In the present application, the numerical range indicated by the term "numerical value a to numerical value B" means a range including the end point numerical value A, B.
In the present application, a numerical range indicated by "above" or "below" is a numerical range including the present number.
In the present application, the meaning of "can" includes both the meaning of performing a certain process and the meaning of not performing a certain process.
In the present application, the use of "optionally" or "optionally" means that certain substances, components, steps performed, conditions applied, etc. are used or not used.
In the present invention, the unit names used are all international standard unit names, and "%" used represent weight or mass% unless otherwise specified.
In the present invention, the terms "about" or "substantially", "essentially" may mean: one value includes the standard deviation of the error of the device or method used to determine the value. The numerical ranges and parameters set forth herein are approximations that may vary depending upon the particular application. However, any numerical value inherently contains certain standard deviations found in their respective testing apparatus or methods. Accordingly, unless expressly stated otherwise, it is to be understood that all ranges, amounts, values and percentages used herein are modified by "about". Herein, "about" generally means that the standard deviation of the actual numerical value from the theoretical model or theoretical data is within 2%, preferably 1%, more preferably 0.5%.
Reference in the present disclosure to "some specific/preferred embodiments," "other specific/preferred embodiments," "an embodiment," etc., means that a particular element (e.g., feature, structure, property, and/or characteristic) described in connection with the embodiment is included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it is to be understood that the elements may be combined in any suitable manner in the various embodiments.
In the present invention, "parts by mass" or "parts by weight" may be any unit by weight such as g, mg, kg or t.
In the present invention, the term "special medical infant formula" refers to a powdered or liquid formula designed for the nutritional needs of infants suffering from a special medical condition such as a particular disorder, disease or medical condition, including formulas suitable for premature/low birth weight infants.
In the present invention, for convenience of expression for fatty acid glycerides, the following characters are used to refer to different kinds of fatty acids: ARA: eicosatetraenoic acid (C20:4); DHA docosahexaenoic acid (C22:6).
In the present invention, when referring to "main component" or "main component" such as fatty acid ester, fat or oil, and mixed structural ester, it means that the content of the corresponding component is higher than the content of other components in the system.
In the present invention, "medium chain fatty acid" named with respect to the chain length of fatty acid means fatty acid having a main chain length of 6 to 12 carbon atoms, and "long chain fatty acid" means fatty acid having a main chain length of more than 12 carbon atoms.
In addition, unless defined otherwise, other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The technical scheme of the invention is mainly completed based on the following findings:
according to the nutritional requirements of premature infants with birth weights < 1kg, the protein content of the fortified formulation for this is up to 3.6g/100kcal, and at least half is derived from whey protein. Although various attempts have been made in the prior art, premature infant fortified formulations meeting the corresponding market needs have not been prepared. The inventor of the present invention has found through a great deal of researches that the reason for this phenomenon is mainly that the existing dry-wet method production process of infant formula powder mainly comprises the steps of mixing, homogenizing, sterilizing, concentrating, spray drying and dry mixing, however, when the preparation method is used for producing a formula with high protein and high whey protein, the whey protein in the feed liquid can be flocculated and denatured through heat treatment, so that the whey protein cannot be produced in a large scale through a spray drying mode, or even if a solid product is produced, the solid product is easy to have lumps, and the brewing usability is poor; and decreasing the heat treatment strength may present a microbiological risk. In this regard, the invention allows for the mass production of high protein, high whey protein fractions and microbiologically acceptable fortifying formulas for premature infants by reasonably improving the manufacturing process thereof while focusing on the total protein and whey protein content of the fortifying formulas for premature infants by spray drying.
The technical scheme of the invention is further described as follows:
nutritional composition suitable for premature infants
The present invention provides a powdered nutritional composition for meeting clinical nutritional needs of middle and late premature infants/low birth weight infants, or very premature infants/very low birth weight infants, preferably ultra premature infants/very low birth weight infants.
In order to meet the clinical nutritional needs of premature infants, especially premature infants/ultra low birth weight infants, at each stage, the present invention provides a powdered nutritional composition comprising: carbohydrates, proteins, fats, minerals and vitamins; and in the nutritional composition, based on the total mass of the nutritional composition: the protein content is more than 3.5g/100kcal, and the whey protein accounts for 60-75 mass% of the total protein. Meanwhile, the preparation method of the nutritional composition at least comprises a spray drying step. And the tap density of the finished product of the powdery nutritional composition provided by the invention is in the range of 180-220mL/100g, preferably 180-200mL/100g. Meanwhile, the cystine content is more than or equal to 0.3g/100g based on the total mass of the powdery nutritional composition provided by the invention.
In some specific embodiments, the nutritional composition comprises: carbohydrates, proteins, fats, minerals, vitamins and nucleotides.
In some specific embodiments, the protein content is 3.6g/100kcal, i.e., the protein content is 17.5g/100g, based on the total mass of the nutritional composition.
In some specific embodiments, whey protein comprises 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, or 75% by mass of the total protein, based on the total mass of the nutritional composition; preferably at a ratio of 60 to 70%, i.e. a whey protein content of 10.5g/100g to 12.3g/100g.
Further, to provide more adequate nutrition while facilitating the preparation of the nutritional composition, the present invention utilizes one or more of the raw materials maltodextrin, skim milk powder, whey protein powder, desalted whey powder, edible fats and oils, lactose, mineral supplements and vitamin supplements to prepare the nutritional composition. The specific sources of the raw materials are not particularly limited, and the raw materials can be purchased from commercial sources, and can be prepared by methods such as biological fermentation and physical purification.
In some specific embodiments, the starting materials of the nutritional composition include maltodextrin, skim milk powder, whey protein powder, desalted whey powder, edible oil and fat, mineral supplements, vitamin supplements, and optionally lactose. In some more specific embodiments, the starting materials of the nutritional composition include maltodextrin, skim milk powder, whey protein powder, desalted whey powder, edible oil and fat, mineral supplements, vitamin supplements, nucleotide supplements, choline chloride, and optionally lactose.
Maltodextrin is a glucose polymer which is prepared by taking starch or starchiness as a raw material and carrying out low-degree hydrolysis, refining and spray drying by an enzyme method and does not contain free starch. Lactose is the primary carbohydrate in breast milk and is also the preferred carbohydrate source for infants. However, compared with term infants, lactase of premature infants is insufficient and has limited capacity of digesting lactose, so that maltodextrin is used for replacing part of lactose, and the decomposition of maltodextrin can be promoted due to stronger activity of the glycosidase of premature infants. In addition, maltodextrin has less effect on the osmotic pressure of the product when supplied with the same energy. In order to better adjust the ratio of the individual nutritional components in the nutritional composition according to the invention, in some specific embodiments the maltodextrin is used in an amount of 220 to 260 parts by weight based on 1000 parts by weight of the total mass of the raw materials of the nutritional composition; illustratively, about 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 255, 260, etc. parts are possible; the preferable dosage is 230-250 parts; more preferably, the amount is 235 to 245 parts; even more preferably in an amount of 238 to 242 parts.
The skim milk powder is prepared from raw milk as raw material by removing milk fat part, and drying. The milk source of the milk powder is not particularly limited, and for example, cow milk, sheep milk and the like may be used, and defatted cow milk powder is preferably used. In order to better provide nutrition to the nutritional composition, in some specific embodiments, the skim milk powder is used in an amount of 200 to 270 parts by weight based on 1000 parts by weight of the total mass of the raw materials of the nutritional composition; illustratively, about 200 parts, 210 parts, 215 parts, 220 parts, 225 parts, 230 parts, 235 parts, 240 parts, 245 parts, 250 parts, 255 parts, 260 parts, 265 parts, 270 parts, or the like; the preferable dosage is 201 to 266 parts; more preferably, the amount is 201 to 255 parts; even more preferably in an amount of 201 to 245 parts.
Whey protein powder is a powdery product with the protein content of not less than 25 mass% which is prepared by taking whey as a raw material through the processes of separation, concentration, drying and the like. In order to make the protein of the nutritional composition more closely resemble breast milk, balancing the whey protein to casein ratio, in some embodiments the whey protein powder is used in an amount of 90 to 130 parts by weight based on 1000 parts by weight total mass of the raw materials of the nutritional composition; illustratively, about 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 125 or 130 parts, etc. are possible; the preferable dosage is 90-125 parts; more preferably, the amount is 90 to 120 parts; even more preferably in an amount of 96 to 118 parts.
The desalted whey powder is a powdery product prepared from whey by desalting and drying, and has a protein content of not less than 10% by mass. In order to make the protein of the nutritional composition more closely resemble breast milk, balancing the whey protein to casein ratio while increasing lactose content and reducing ash content, in some embodiments the desalted whey powder is used in an amount of 100 to 150 parts by weight based on 1000 parts by weight total mass of the starting materials of the nutritional composition; illustratively, about 100 parts, 101 parts, 103 parts, 105 parts, 109 parts, 110 parts, 111 parts, 113 parts, 115 parts, 119 parts, 120 parts, 125 parts, 130 parts, 135 parts, 140 parts, 145 parts, 150 parts, or the like; the preferable dosage is 100-145 parts; more preferably, the amount is 101 to 142 parts.
Also, to better adjust the content of whey protein and total protein, in some embodiments, the total content of skim milk powder, whey protein powder, and desalted whey powder may be controlled, illustratively, the total addition of the above three materials is not less than 400 parts by weight and not more than 500 parts by weight, preferably not less than 420 parts by weight and not more than 485 parts by weight, more preferably not less than 440 parts by weight and not more than 475 parts by weight, even more preferably not less than 450 parts by weight and not more than 465 parts by weight, based on the total mass of the raw materials of the nutritional composition of 1000 parts by weight.
In order to provide comprehensive nutrition, so that the fatty acid structure in the final nutritional composition is more reasonable to meet the nutritional requirements of premature infants, the invention utilizes various edible fats to supply the fat components. In some embodiments, the edible oil comprises one or more of vegetable oil, medium chain triglycerides, arachidonic acid oil, and docosahexaenoic acid oil. In some specific embodiments, the edible fats and oils include vegetable oils, medium chain triglycerides, arachidonic acid fats and oils, and docosahexaenoic acid fats and oils.
In order to increase and balance monounsaturated fatty acids, polyunsaturated fatty acids, and medium and long chain fatty acids, etc. in the nutritional composition, in some embodiments, the present invention utilizes mixed vegetable oils, arachidonic acid oleoresin powder, and docosahexaenoic acid oleoresin powder as sources of fat.
The mixed vegetable oil refers to edible oil prepared by blending two or more edible vegetable oils prepared from edible vegetable oil or crude vegetable oil. And, in order to increase the medium chain fatty acid therein, medium chain triglycerides are also added to the mixed vegetable oil, and the fat content in the medium chain triglyceride product is not less than 65 mass%. In some specific embodiments, the blended vegetable oil consists of: 70-80 parts of medium chain triglyceride, 55-65 parts of high oleic acid sunflower seed oil, 50-60 parts of sunflower seed oil and 45-55 parts of low erucic acid rapeseed oil, wherein medium chain fat accounts for 27% -36% of total fat.
The arachidonic acid oil powder is a powder product obtained by adding adjuvants such as whey protein powder, whey powder, modified starch, maltodextrin, lactose, white sugar, acacia, sodium starch octenyl succinate, sodium caseinate, vitamin E, and ascorbyl palmitate to arachidonic acid oil (which can be derived from Mortierella alpina or the like and can be prepared by biological fermentation). Wherein the fat content in the arachidonic acid oil fat powder is not less than 20 mass%, and the content of the arachidonic acid is not less than 10 mass%.
The docosahexaenoic acid oil powder is a powder product prepared by adding adjuvants such as whey protein powder, whey powder, modified starch, maltodextrin, lactose, white sugar, acacia, sodium starch octenyl succinate, sodium caseinate, vitamin E, and ascorbyl palmitate into docosahexaenoic acid oil (which can be prepared by biological fermentation from Schizochytrium, uyghur Cryptotaenia, tuna oil, etc.) as raw materials. Wherein the fat content in the docosahexaenoic acid grease powder is not less than 20% by mass, and the content of the docosahexaenoic acid is not less than 7% by mass.
In some embodiments, the mixed vegetable oil is used in an amount of 220 to 260 parts by weight based on 1000 parts by weight of the total mass of the starting materials of the nutritional composition; illustratively, about 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 255, 260, etc. parts are possible; the preferable dosage is 230-255 parts; more preferably, the amount is 230 to 250 parts; even more preferably in an amount of 230 to 240 parts.
In some embodiments, the arachidonic acid oil fat powder is used in an amount of 11 to 15 parts by weight based on 1000 parts by weight of the total mass of the starting materials of the nutritional composition; illustratively, about 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, etc.; the preferable amount is 12 to 14 parts.
In some embodiments, the docosahexaenoic acid oil fat powder is used in an amount of 9 to 13 parts by weight based on 1000 parts by weight of the total mass of the starting materials of the nutritional composition; illustratively, about 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, etc.; the preferable amount is 10 to 12 parts.
Furthermore, the addition of lactose is not necessary in the nutritional composition in order to better provide energy, promoting the absorption of calcium by premature infants. In some embodiments, the lactose is used in an amount of 0-15 parts; illustratively, about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, etc. parts are possible; the preferable dosage is 0-10 parts; more preferably in an amount of 0 to 8 parts; even more preferably in an amount of 0 to 5 parts.
In order to provide various minerals, vitamins and nucleotides, the invention utilizes compound minerals, compound vitamins, compound nucleotides and choline chloride as supplements.
In order to facilitate the subsequent preparation of the nutritional composition, the complex minerals are divided into complex mineral-1 and complex mineral-2. In some embodiments, the compounded mineral-1 consists of: 9 to 11 parts of tricalcium phosphate, 4 to 5 parts of sodium chloride, 3 to 4 parts of calcium carbonate, 2 to 2.5 parts of magnesium sulfate, 1.5 to 2.5 parts of dipotassium hydrogen phosphate, 1.5 to 2 parts of sodium citrate, 0.4 to 0.7 part of potassium citrate, 0.3 to 0.6 part of potassium chloride and 0.5 to 2 parts of maltodextrin. In some embodiments, the compounded mineral-2 consists of: 0.4 to 0.7 part of ferric pyrophosphate, 0.1 to 0.3 part of zinc sulfate, 0.1 to 0.3 part of potassium iodate, 0.05 to 0.15 part of copper sulfate, 0.02 to 0.08 part of sodium selenite, 0.01 to 0.02 part of manganese sulfate and 0.5 to 1.5 part of maltodextrin.
In some embodiments, the built vitamin consists of the following ingredients: 2 to 3 parts of L-sodium ascorbate, 0.8 to 1.5 parts of inositol, 0.4 to 1.4 parts of dl-alpha-tocopheryl acetate, 0.3 to 0.6 part of taurine, 0.1 to 0.4 part of L-carnitine, 0.1 to 0.3 part of retinyl acetate, 0.1 to 0.2 part of nicotinamide, 0.1 to 0.15 part of cholecalciferol, 0.04 to 0.08 part of D-calcium pantothenate, 0.01 to 0.03 part of riboflavin, 0.01 to 0.02 part of thiamine nitrate, 0.01 to 0.02 part of pyridoxine hydrochloride, 0.02 to 0.04 part of folic acid, 0.02 to 0.04 part of D-biotin, 0.02 to 0.04 part of cyanocobalamine, 0.01 to 0.02 part of phytomenadione, and 0.5 to 1.5 parts of maltodextrin.
In some embodiments, the compound nucleotide contains 0.17-0.27 part of 5' -cytidine disodium, 0.07-0.12 part of 5' -uridine disodium, 0.7-0.11 part of 5' -adenosine monophosphate, 0.05-0.09 part of 5' -guanylate disodium and 0.02-0.04 part of 5' -inosinic acid disodium.
In some embodiments, the compounded mineral-1 is used in an amount of 25-28 parts by weight based on 1000 parts by weight of the total mass of the starting materials of the nutritional composition; illustratively, about 25 parts, 25.5 parts, 26 parts, 26.5 parts, 27 parts, 27.5 parts, 28 parts, etc.; the preferable dosage is 25-27 parts; more preferably, the amount is 25.5 to 27 parts.
In some embodiments, the amount of the compounded mineral-2 is 1.5-2 parts by weight based on 1000 parts by weight of the total mass of the starting materials of the nutritional composition; illustratively, about 1.5 parts, 1.75 parts, or 2 parts may be used.
In some embodiments, the amount of the built vitamin is from 5 to 7 parts by weight based on 1000 parts by weight total mass of the starting materials of the nutritional composition; illustratively, about 5 parts, 6 parts, 7 parts, etc.
In some embodiments, the compounded nucleotide is used in an amount of 0.4 to 0.6 parts by weight based on 1000 parts by weight of the total mass of the starting materials of the nutritional composition; illustratively, about 0.4 parts, 0.5 parts, or 0.6 parts, etc.
In addition, the present invention utilizes choline chloride to increase the choline content of the nutritional composition, in some embodiments, the choline chloride is used in an amount of 1.0 to 1.5 parts by weight based on 1000 parts by weight of the total mass of the raw materials of the nutritional composition; illustratively, about 1.0 part, 1.25 parts, or 1.5 parts may be used.
Further, in some specific embodiments, the nutritional composition comprises the following raw materials in parts by weight, based on 1000 parts by weight total mass of the raw materials of the nutritional composition: 220-260 parts of maltodextrin, 220-260 parts of mixed vegetable oil, 200-270 parts of skim milk powder, 100-150 parts of desalted whey powder, 90-130 parts of whey protein powder, 0-15 parts of lactose, 25-28 parts of compound mineral matter, 11-15 parts of arachidonic acid grease powder, 9-13 parts of docosahexaenoic acid grease powder, 5-7 parts of compound vitamin, 1.5-2 parts of compound mineral matter, 1.0-1.5 parts of choline chloride and 0.4-0.6 part of compound nucleotide.
Method for preparing nutritional composition suitable for premature infants
The invention also provides a preparation method of the powdery nutritional composition suitable for premature infants, which comprises the following steps: a step of mixing a raw material component I comprising carbohydrate and protein with water to obtain a premix liquid; a step of micro-filtration sterilization of the premix liquid; mixing the premixed material liquid after micro-filtration sterilization with a raw material component II comprising fat, homogenizing, concentrating, and spray drying to obtain semi-finished powder; and a step of dry-blending the semi-finished powder with a raw material component III comprising minerals, vitamins and fat.
In some embodiments, the feedstock component I comprises one or more of maltodextrin, skim milk powder, whey protein powder, desalted whey powder, and lactose. In addition, the raw material component I does not comprise fat in order to facilitate the subsequent sterilization by a microfiltration method. In some specific embodiments, the specific operation of the step of mixing the feedstock component I comprising carbohydrates and proteins with water to obtain a premix liquid may be: adding production water into a vacuum mixing tank, heating to 40-50 ℃, adding maltodextrin, optional lactose, whey protein powder, skim milk powder and desalted whey powder, and maintaining vacuum stirring to obtain premixed feed liquid.
In some specific embodiments, the specific operation of the step of micro-filtering the premix feed solution may be: the premixed feed liquid is subjected to microfiltration sterilization by a ceramic membrane, the microfiltration temperature is 40-50 ℃, preferably 42-48 ℃, and the aperture of the microfiltration membrane is 0.8-1.6 mu m, preferably 1.2-1.4 mu m.
In some embodiments, the feedstock component II comprises edible fats and oils, including vegetable oils and medium chain triglycerides. In some specific embodiments, the feedstock component II is a mixed vegetable oil. In some specific embodiments, the steps of mixing the premixed liquid after micro-filtration sterilization with the raw material component II comprising fat, homogenizing, concentrating and drying to obtain semi-finished powder can be specifically performed as follows: preheating the sterilized premix liquid, mixing the premix liquid with on-line metering vegetable oil after preheating to 45-55 ℃, and homogenizing the mixture under the homogenizing pressure of 20-30 MPa; concentrating the homogenized feed liquid by a triple effect evaporator until the concentration of the feed liquid is 35% -45%, preferably 35% -40%; spray drying the concentrated feed liquid at 160-200deg.C and 75-95deg.C.
In some embodiments, between the steps of homogenizing and concentrating and drying, a step of pasteurizing the homogenized feed solution is further included. In some specific embodiments, the pasteurization temperature is 72 to 76 ℃ and the sterilization time is 15 to 20 seconds. The secondary sterilization at a lower temperature is added before concentration, so that the microbial risk of the finished product can be further reduced.
In some embodiments, the feedstock component III includes a complex mineral, a complex vitamin, a complex nucleotide, choline chloride, an arachidonic acid oleoresin powder, and an docosahexaenoic acid oleoresin powder. In some specific embodiments, the specific operation of the step of dry blending the semi-finished powder with raw material component III comprising minerals, vitamins, nucleotides and fat may be: and (3) carrying out dry mixing on the semi-finished powder, the compound mineral-1, the compound mineral-2, the compound vitamin, the compound nucleotide, the arachidonic acid oil fat powder, the docosahexaenoic acid oil fat powder and the choline chloride, wherein the dry mixing rotating speed is 50rpm, and the dry mixing time is 2-4 min.
In addition, in order to improve the uniformity of the dry mixing step, in some embodiments, the compound mineral-2, the compound vitamin, the choline chloride and the compound nucleotide can be respectively premixed and amplified with the semi-finished product powder, the premixing proportion is respectively and independently 1:1-1:10 in terms of mass ratio, the premixing time is 1-3 min, and then the semi-finished product powder is mixed with other ingredients.
The preparation method provided by the invention adopts a microfiltration technology and an on-line adding mode of grease to overcome the problems of denaturation and flocculation of a formula with high protein and high whey protein ratio after heat treatment, and timely increases pasteurization according to the microbial level of the material to perform secondary sterilization, so that the microbial risk is further reduced. The difference from the existing preparation process is detailed in the preparation process flow charts shown in fig. 1 and 2.
Examples
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
Example 1
A high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following components in parts by weight:
238 parts of maltodextrin, 237 parts of mixed vegetable oil, 235 parts of skim milk powder, 108 parts of whey protein powder, 119 parts of desalted whey powder, 1.5 parts of compound mineral, 13 parts of arachidonic acid oil powder, 11 parts of docosahexaenoic acid oil powder, 6 parts of compound vitamin, 3 parts of lactose, 1.75 parts of compound mineral, 1.25 parts of choline chloride and 0.5 part of compound nucleotide.
The mixed vegetable oil consists of the following components: 76 parts of medium chain triglyceride, 59 parts of high oleic acid sunflower seed oil, 55 parts of sunflower seed oil and 47 parts of canola oil, wherein the medium chain fat accounts for 32% of the total fat.
The compound mineral substance-1 consists of the following components: 9.9 parts of tricalcium phosphate, 4.5 parts of sodium chloride, 3.3 parts of calcium carbonate, 2.2 parts of magnesium sulfate, 1.9 parts of dipotassium hydrogen phosphate, 1.8 parts of sodium citrate, 0.54 part of potassium citrate, 0.45 part of potassium chloride and 1.91 parts of maltodextrin.
The compound vitamin consists of the following components: 2.51 parts of L-sodium ascorbate, 1.13 parts of inositol, 0.87 part of dl-alpha-tocopheryl acetate, 0.43 part of taurine, 0.24 part of L-carnitine, 0.22 part of retinyl acetate, 0.15 part of nicotinamide, 0.12 part of cholecalciferol, 0.06 part of D-calcium pantothenate, 0.02 part of riboflavin, 0.01 part of thiamine nitrate, 0.01 part of pyridoxine hydrochloride, 0.03 part of folic acid, 0.03 part of D-biotin, 0.03 part of cyanocobalamin, 0.01 part of phytomenaquinone and 0.13 part of maltodextrin.
The compound mineral substance-2 consists of the following components: 0.54 part of ferric pyrophosphate, 0.18 part of zinc sulfate, 0.18 part of potassium iodate, 0.09 part of copper sulfate, 0.05 part of sodium selenite, 0.01 part of manganese sulfate and 0.7 part of maltodextrin.
The compound nucleotide is purchased from Nanjing Hokken Kai biotechnology Co., ltd, the arachidonic acid oil and fat powder and the docosahexaenoic acid oil and fat powder are purchased from Roguet biological nutrition (Wuhan) Co., ltd, the skim milk powder is purchased from Kerry Ingredients (Ireland) Ltd, the whey protein powder is purchased from Wheyco, germany, the desalted whey powder is purchased from DOMO, the maltodextrin is purchased from Shandong Baolin, the lactose is purchased from ARLA, and the choline chloride is purchased from Beijing kangpe.
A method for preparing a high protein, high whey protein ratio fortified formulation for premature infants, comprising the steps of:
s01, mixing carbohydrate and protein: adding production water into a vacuum mixing tank, heating to 45 ℃, adding maltodextrin, lactose, whey protein powder, skim milk powder and desalted whey powder, and maintaining vacuum stirring for 5min to obtain premixed feed liquid.
S02, microfiltration: the premix liquid is subjected to microfiltration sterilization by a ceramic membrane, the microfiltration temperature is 45 ℃, and the aperture of the microfiltration membrane is 1.4 mu m.
S03, oiling and homogenizing: preheating the sterilized premix liquid, mixing the premix liquid with the on-line metering vegetable oil after preheating to 50 ℃, and homogenizing the mixture under the homogenizing pressure of 25MPa.
S04, concentrating and drying: the homogenized feed liquid is concentrated by a triple effect evaporator until the mass percentage of the dry matter of the feed liquid is 38%. Spray drying the concentrated feed liquid, wherein the inlet air temperature of the drying tower is 175 ℃ and the exhaust air temperature of the drying tower is 90 ℃.
S05, cooling the fluidized bed: the temperature of the semi-finished powder is controlled to be less than or equal to 35 ℃ through four sections of cooling of the fluidized bed.
S06, dry mixing: and carrying out dry mixing on the semi-finished powder, the compound mineral-1, the compound mineral-2, the compound vitamin, the compound nucleotide, the choline chloride, the arachidonic acid oil fat powder and the docosahexaenoic acid oil fat powder, wherein the dry mixing rotating speed is 50rpm, and the dry mixing time is 3min.
S07, packaging and detecting.
The protein content of the final product prepared in this example was 3.6g/100kcal (17.5 g/100 g), the whey protein content in the total protein was 65% (11.3 g/100 g), the tap density of the final product powder was 190mL/100g, the cystine content was 0.33g/100g, and the detection results of the total number of colonies in the preparation process and the final product were as follows:
TABLE 1 detection results of the total number of colonies in the preparation process and the finished products
Example 2
This embodiment differs from embodiment 1 in that: a high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following components in parts by weight:
240 parts of maltodextrin, 237 parts of mixed vegetable oil, 266 parts of skim milk powder, 96 parts of whey protein powder, 101 parts of desalted whey powder, 1.5 parts of compound mineral, 13 parts of arachidonic acid oil powder, 11 parts of docosahexaenoic acid oil powder, 6 parts of compound vitamin, 1.75 parts of compound mineral, 1.25 parts of choline chloride and 0.5 part of compound nucleotide. Wherein the specific composition and sources of each raw material are the same as in example 1.
The preparation method of the premature infant fortified formulation in this example is the same as that of the premature infant fortified formulation in example 1.
The final product prepared in this example had a protein content of 3.6g/100kcal (17.5 g/100 g), a whey protein content of 60% (10.5 g/100 g) in the total protein, a tap density of 184mL/100g, and a cystine content of 0.31g/100g.
Example 3
This embodiment differs from embodiment 1 in that: a high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following components in parts by weight:
242 parts of maltodextrin, 237 parts of mixed vegetable oil, 201 parts of skim milk powder, 118 parts of whey protein powder, 142 parts of desalted whey powder, 1.5 parts of compound mineral, 13 parts of arachidonic acid oil powder, 11 parts of docosahexaenoic acid oil powder, 6 parts of compound vitamin, 1.75 parts of compound mineral, 1.25 parts of choline chloride and 0.5 part of compound nucleotide. Wherein the specific composition and sources of each raw material are the same as in example 1.
The preparation method of the premature infant fortified formulation in this example is the same as that of the premature infant fortified formulation in example 1.
The protein content of the final product prepared in this example was 3.6g/100kcal (17.5 g/100 g), the whey protein content in the total protein was 70% (12.3 g/100 g), the tap density of the final product powder was 198mL/100g, and the cystine content was 0.36g/100g.
Example 4
The composition of the high protein, high whey protein ratio preterm formula in this example was the same as the composition of the preterm formula in example 1.
This embodiment differs from embodiment 1 in that: a preparation method of a high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following steps:
s01, mixing carbohydrate and protein: adding production water into a vacuum mixing tank, heating to 45 ℃, adding maltodextrin, lactose, whey protein powder, skim milk powder and desalted whey powder, and maintaining vacuum stirring for 5min to obtain premixed feed liquid.
S02, microfiltration: the premix liquid is subjected to microfiltration sterilization by a ceramic membrane, the microfiltration temperature is 45 ℃, and the aperture of the microfiltration membrane is 1.4 mu m.
S03, oiling and homogenizing: preheating the sterilized premix liquid, mixing the premix liquid with the on-line metering vegetable oil after preheating to 50 ℃, and homogenizing the mixture under the homogenizing pressure of 25MPa.
S04, pasteurization: and pasteurizing the homogenized feed liquid at 75 ℃ for 15s.
S05, concentrating and drying: the feed liquid is concentrated by a triple effect evaporator until the mass percentage of the dry matter of the feed liquid is 38%. Spray drying the concentrated feed liquid, wherein the inlet air temperature of the drying tower is 175 ℃ and the exhaust air temperature of the drying tower is 90 ℃.
S06, cooling the fluidized bed: the temperature of the semi-finished powder is controlled to be less than or equal to 35 ℃ through four sections of cooling of the fluidized bed.
S07, dry mixing: and mixing the semi-finished powder with compound mineral-1, compound mineral-2, compound vitamin, choline chloride, compound nucleotide, arachidonic acid oil and fat powder and docosahexaenoic acid oil and fat powder in a dry mode, wherein the dry mixing speed is 50rpm, and the dry mixing time is 3min.
S08, packaging and detecting.
In this example, the protein in the feed liquid after concentration in the preparation process S05 has no obvious denaturation or flocculation, as shown in FIG. 3. The tap density of the finished powder is 188mL/100g.
Example 5
The composition of the high protein, high whey protein ratio preterm formula in this example was the same as the composition of the preterm formula in example 1.
This embodiment differs from embodiment 1 in that: a preparation method of a high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following steps:
S01, mixing carbohydrate and protein: adding production water into a vacuum mixing tank, heating to 45 ℃, adding maltodextrin, lactose, whey protein powder, skim milk powder and desalted whey powder, and maintaining vacuum stirring for 5min to obtain premixed feed liquid.
S02, microfiltration: the premix liquid is subjected to microfiltration sterilization by a ceramic membrane, the microfiltration temperature is 45 ℃, and the aperture of the microfiltration membrane is 1.4 mu m.
S03, oiling and homogenizing: preheating the sterilized premix liquid, mixing the premix liquid with the on-line metering vegetable oil after preheating to 50 ℃, and homogenizing the mixture under the homogenizing pressure of 25MPa.
S04, concentrating and drying: the feed liquid is concentrated by a triple effect evaporator to 38 percent of the feed liquid concentration. Spray drying the concentrated feed liquid, wherein the inlet air temperature of the drying tower is 175 ℃ and the exhaust air temperature of the drying tower is 90 ℃.
S05, cooling the fluidized bed: the temperature of the semi-finished powder is controlled to be less than or equal to 35 ℃ through four sections of cooling of the fluidized bed.
S06, premixing: the compound mineral-2, the compound vitamin and the choline chloride are respectively premixed with the semi-finished product powder according to the mass ratio of 1:5, and the compound nucleotide and the semi-finished product powder are premixed according to the mass ratio of 1:10 for 2min.
S07, dry mixing: and (3) carrying out dry mixing on the semi-finished powder, the premixed raw materials, the compound mineral-1, the arachidonic acid oil powder and the docosahexaenoic acid oil powder, wherein the dry mixing rotating speed is 50rpm, and the dry mixing time is 3min.
S08, packaging and detecting.
In the embodiment, the preparation process is smooth and has no abnormality, and the tap density of the finished powder is 184mL/100g.
Comparative example 1
The composition of the components of the premature infant fortified formulation in this comparative example was the same as that of the premature infant fortified formulation in example 1.
The difference between this comparative example and example 1 is that: the high-protein and high-whey-protein-ratio premature infant fortified formulation is prepared by a general preparation method in the prior art:
s01, batching: adding purified water into a vacuum mixing tank, heating to 50 ℃, adding whey protein powder, skim milk powder, desalted whey powder, maltodextrin and lactose, adding mixed vegetable oil, maintaining vacuum stirring, sequentially adding pre-dissolved compound mineral-1, choline chloride, compound nucleotide, compound mineral-2 and compound vitamin, and stirring for 5min after all raw materials are added to obtain a premix liquid;
s02, homogenizing: homogenizing the premix liquid at 50 ℃ with the total homogenizing pressure of 25MPa.
S03, sterilizing: and (3) sterilizing the homogenized feed liquid by adopting DSI, wherein the sterilization temperature is 85 ℃, and the sterilization time is 20s.
S04, concentrating: the sterilized feed liquid is concentrated by a triple effect evaporator until the mass percentage of the dry matter of the feed liquid is 45%.
In the comparative example, the feed liquid undergoes sterilization until gel flocculation occurs in the concentration process, and the solid product is finally obtained, as shown in fig. 4.
Although comparative example 1 gave a product with good nutrition, the solid product was poorly flushable.
Comparative example 2
The difference between this comparative example and example 1 is that: a high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following components in parts by weight:
345 parts of skim milk powder, 237 parts of mixed vegetable oil, 230 parts of maltodextrin, 78 parts of whey protein powder, 50 parts of desalted whey powder, 1.5 parts of compound mineral, 13 parts of arachidonic acid oil powder, 11 parts of docosahexaenoic acid oil powder, 6 parts of compound vitamin, 2.75 parts of compound mineral, 1.25 parts of choline chloride and 0.5 part of compound nucleotide. Wherein the specific composition and sources of each raw material are the same as in example 1.
The preparation method of the premature infant fortified formulation in this comparative example was the same as that of the premature infant fortified formulation in example 1.
The protein content of the final product prepared in this example was 3.6g/100kcal (17.6 g/100 g), the whey protein content of the total protein was 50% (8.8 g/100 g), and the cystine content was 0.28g/100g.
Therefore, under the composition of raw materials with high protein and low whey protein ratio, the preparation process provided by the application can still smoothly prepare powder products through spray drying, but the content of cysteine (cystine) in the formula can not meet the nutritional requirements of premature infants due to the too low content of whey protein.
Comparative example 3:
the difference between this comparative example and example 1 is that: a high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following components in parts by weight:
243 parts of maltodextrin, 236 parts of mixed vegetable oil, 178 parts of desalted whey powder, 145 parts of whey protein powder, 138 parts of skim milk powder, 1.5 parts of compound mineral, 13 parts of arachidonic acid oil powder, 11 parts of docosahexaenoic acid oil powder, 6 parts of compound vitamin, 1.75 parts of compound mineral, 1.25 parts of choline chloride and 0.5 part of compound nucleotide. Wherein the specific composition and sources of each raw material are the same as in example 1.
The preparation method of the premature infant fortified formulation in this comparative example was the same as that of the premature infant fortified formulation in example 1.
The protein content of the finished product prepared in the comparative example is 3.6g/100kcal (17.6 g/100 g), the whey protein accounts for 80 percent (14.1 g/100 g) of the total protein, but the prepared formula powder has finer particles, is easy to cause blockage during subsequent pipeline transportation, brings inconvenience to the process steps of filling and the like, and has poor solubility and poor usability.
Comparative example 4:
the difference between this comparative example and example 1 is that: a high-protein and high-whey-protein-ratio premature infant fortified formula powder comprises the following components in parts by weight:
245 parts of mixed vegetable oil, 223 parts of maltodextrin, 196 parts of desalted whey powder, 195 parts of skim milk powder, 81 parts of whey protein powder, 1.5 parts of compound mineral, 13 parts of arachidonic acid oil powder, 11 parts of docosahexaenoic acid oil powder, 6 parts of compound vitamin, 1.75 parts of compound mineral, 1.25 parts of choline chloride and 0.5 part of compound nucleotide. Wherein the specific composition and sources of each raw material are the same as in example 1.
The preparation method of the premature infant fortified formulation in this comparative example is the same as that of comparative example 1.
The protein content of the final product prepared in this comparative example was 3.0g/100kcal (15 g/100 g), and the whey protein content in the total protein was 65% (9.75 g/100 g).
It can be seen that the powder product prepared by the conventional preparation process under the raw material composition of low protein and high whey protein ratio can not meet the nutritional requirements of premature infants in all stages, especially ultra-premature infants/ultra-low birth weight infants, though the powder product can be prepared by spray drying.
Industrial applicability
The powdered nutritional composition suitable for premature infants and the preparation method thereof provided by the invention can be industrially implemented.
Claims (10)
1. A nutritional composition suitable for use in premature infants, the nutritional composition comprising: carbohydrates, proteins, fats, minerals and vitamins;
And in the nutritional composition, based on the total mass of the nutritional composition: the protein content is more than 3.5g/100kcal, and the whey protein accounts for 60-75% of the total protein by mass;
and, the nutritional composition is a powdered solid.
2. The nutritional composition of claim 1, wherein the starting material of the nutritional composition comprises one or more of maltodextrin, skim milk powder, whey protein powder, desalted whey powder, edible oil, lactose, mineral supplements and vitamin supplements.
3. The nutritional composition of claim 2, wherein the edible oil comprises one or more of vegetable oil, medium chain triglycerides, arachidonic acid oil, and docosahexaenoic acid oil.
4. A nutritional composition according to any one of claims 1-3, characterized in that the tap density of the nutritional composition is in the range of 180-220mL/100g.
5. Process for the preparation of a nutritional composition according to any one of claims 1 to 4, characterized in that it comprises the following steps:
a step of mixing a raw material component I comprising carbohydrate and protein with water to obtain a premix liquid;
A step of micro-filtration sterilization of the premix liquid;
mixing the premixed material liquid after micro-filtration sterilization with a raw material component II comprising fat, homogenizing, concentrating, and spray drying to obtain semi-finished powder;
and a step of dry-blending the semi-finished powder with a raw material component III comprising minerals, vitamins and fat.
6. The method according to claim 5, further comprising, between the homogenizing and concentrating steps, a step of pasteurizing the homogenized feed solution.
7. The method according to claim 5 or 6, wherein the temperature of the microfiltration is 40-50 ℃ and the pore size of the microfiltration membrane is 0.8-1.6 μm.
8. The preparation method according to any one of claims 5 to 7, wherein the raw material component I comprises one or more of maltodextrin, skim milk powder, whey protein powder, desalted whey powder and lactose.
9. The method according to any one of claims 5 to 8, wherein the raw material component II comprises edible fats and oils including vegetable oils and medium chain triglycerides.
10. The preparation method according to any one of claims 5 to 9, wherein the raw material component III comprises mineral supplement, vitamin supplement, arachidonic acid oleoresin powder and docosahexaenoic acid oleoresin powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311238234.5A CN117223848A (en) | 2023-09-22 | 2023-09-22 | Powdered nutritional composition suitable for premature infants and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311238234.5A CN117223848A (en) | 2023-09-22 | 2023-09-22 | Powdered nutritional composition suitable for premature infants and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117223848A true CN117223848A (en) | 2023-12-15 |
Family
ID=89092633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311238234.5A Pending CN117223848A (en) | 2023-09-22 | 2023-09-22 | Powdered nutritional composition suitable for premature infants and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117223848A (en) |
-
2023
- 2023-09-22 CN CN202311238234.5A patent/CN117223848A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100456936C (en) | Infant formula compositions comprising increased amounts of alpha-lactalbumin | |
| RU2455857C2 (en) | Nutritional composition | |
| CN103070241B (en) | Infant-formula goat milk powder of pure goat milk protein and preparation method thereof | |
| SE457501B (en) | HUMANIZED MOTHER'S MILK COMPOSITION, PROVIDED WITH NUCLEOTIDES AND SET FOR ITS PREPARATION | |
| CN105614103A (en) | Fat powder for early-phase weaned piglets and production method of fat powder | |
| EP2026791A1 (en) | Maternal supplement | |
| CN108522655A (en) | The baby milk and preparation method of micro functional active components in a kind of across-the-board regulation formula | |
| CN105532919B (en) | A kind of full nutrition children prescription emulsifiable powder and preparation method thereof | |
| CN110786388A (en) | Milk powder for promoting growth of children and preparation method thereof | |
| CN105558060A (en) | Nutrient-rich pregnant mother milk powder and preparation method thereof | |
| WO2022174606A1 (en) | Infant formula milk powder rich in structured lipid opl, and preparation method therefor | |
| CN109527116A (en) | A kind of premature labor/low birth weight baby formula food and preparation method thereof | |
| EP1549158B1 (en) | Infant formula containing nucleotides | |
| CN101427792A (en) | Liquid milk with additive arachidonic acid (AA) suitable for baby of 6 to 12 months old | |
| CN117481199A (en) | Premature/low birth weight infant food for promoting growth and development, and preparation method and application thereof | |
| CN111919889A (en) | Mother-emulsified infant formula goat milk powder capable of improving immunity and preparation method thereof | |
| CN103609748A (en) | Hypoglycaemic milk powder for pregnant women and preparation method thereof | |
| CN117223848A (en) | Powdered nutritional composition suitable for premature infants and preparation method thereof | |
| KR101249082B1 (en) | Infant formula containing hydrolyzed whey powder, hydrolyzed skin milk powder preparation and β-casein | |
| CN114431304A (en) | A second-stage infant formula milk powder with donkey milk as base material and its preparation method | |
| RU2703172C2 (en) | Feeding for infants with hydrolysed protein and palmitic acid | |
| CN101317596B (en) | Liquid milk for baby of 12 to 36 months age and method for using on-line addition technique thereof | |
| US20210037854A1 (en) | Eggs rich in nutrients of alpha-linolenic acid and dha, breeding method of laying hens, and feed additive | |
| RU2384069C1 (en) | Formula for production of sterilised milk product of baby food based on goat's milk from birth to five months of age | |
| CN117137008A (en) | Pregnant woman and lactating mother nutrition supplementing composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |